$PHARM News
Last published 1mo ago
- 1mo agoPHARMPHARPharming announces positive Phase II topline data for leniolisib in PIDs with immune dysregulation accepted as late-breaking abstract at ESID 2026GlobeNewswireLeniolisib was generally well-tolerated, with clinical improvements across multiple measures of immune dysregulation, including reductions in lymphoproliferation Separately, Pharming expects to report topline results
- 2mo agoPHARMPHARFDA approves Pharming’s Joenja® as first treatment for children with APDS in the U.S.GlobeNewswireFDA approval expands Joenja indication to include children with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) ages 4 to 11 who weigh at least 27kgNewly approved Joenja doses are expected to be
- 2mo agoPHARMPHARPharming Group to participate in September investor conferencesGlobeNewswireLeiden, the Netherlands, September 9, 2026: Pharming Group N.V. ("Pharming") (NASDAQ:PHAR) today announced that its management will participate in the following investor conferences in the month of September:
- 3mo agoPHARMPHARPharming announces commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with APDS aged 4 and olderGlobeNewswireLaunch marks first commercial availability of Joenja® (leniolisib) for children aged 4 to 11 worldwide OrphanPacific, Inc. serves as Marketing Authorization holder and is responsible for supply and distribution in Japan
- 3mo agoPHARMPHARPharming Group to participate in Canaccord Genuity 46th Annual Growth ConferenceGlobeNewswireLeiden, the Netherlands, August 4, 2026: Pharming Group N.V. (NASDAQ:PHAR), today announced its participation in the Canaccord Genuity 46th Annual Growth Conference in Boston on August 12-13, 2026. Michael Levitan, VP
- 3mo agoPHARMPHARPharming reports second quarter and first half 2026 financial results and revises year-end guidance; strong Joenja momentum and near-term clinical readouts to support broader therapeutic useGlobeNewswireFor investor audiences and media only Second quarter 2026 total revenues decreased by 3% to US$90.2 million, compared to the second quarter 2025RUCONEST® revenue was US$72.3 million, a 10% decrease compared to the
- 3mo agoPHARMPHARPharming Group to report second quarter and first half 2026 financial results and provide business update on July 30GlobeNewswireLeiden, the Netherlands, July 16, 2026: Pharming Group N.V. ("Pharming") (NASDAQ:PHAR) confirms that it will report its preliminary (unaudited) financial results for the second quarter and first half 2026 and